BOT - Anything but charting, page-7068

Without adjusting for US population and growth and other de-risked ( due to funding) pipeline

remember 3 things:

1. Japan sales as it is today already have 300 000 prescribtions annually...and still Growing at over 45% yoy!!!
growth
just this 300 000 prescribtions- would justify aud3bln valuation as it gives us over 200mln Sales p.a. and still Growing !

2. US 3x population gives us upside of 3x...this investor gets for free, assuming you believe in at least 300 000 prescribtions p.a
3. Japan growth is still strong - investor who just believes in 300k prescriptions not more will get it dor free
i will not go to de- risked pipeline of products ( since we will have $$ to fund its Ph3 and Ph2) - this in its own would worth at least 500mln as being advanced...


so, investor buying today gets upside to $2 per share just on 300k prescriptionswe know today, free growth based on japan 45% yoy growth, free 3x upside due to US population, and free upside due to derisked ( funded) pipeline of other derm advanced products...

on FDA approval and continuing confirmation of Japan growth we should see$1
i call it $3 per share as a base range valuation but i see it higher!